%PDF-1.4
1 0 obj
<<
/Title ( F u s i o n P h a r m a c e u t i c a l s A n n o u n c e s F i r s t Q u a r t e r 2 0 2 1 F i n a n c i a l R e s u l t s a n d B u s i n e s s U p d a t e - M a y 1 1 , 2 0 2 1)
/Creator ( w k h t m l t o p d f 0 . 1 2 . 4)
/Producer ( Q t 4 . 8 . 7)
/CreationDate (D:20240328104440-04'00')
>>
endobj
3 0 obj
<<
/Type /ExtGState
/SA true
/SM 0.02
/ca 1.0
/CA 1.0
/AIS false
/SMask /None>>
endobj
4 0 obj
[/Pattern /DeviceRGB]
endobj
8 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [238.500000 661.500000 284.250000 669.750000 ]
/Border [0 0 0]
/A <<
/Type /Action
/S /URI
/URI (http://www.prnewswire.com/)
>>
>>
endobj
9 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [157.500000 448.500000 474 456.750000 ]
/Border [0 0 0]
/A <<
/Type /Action
/S /URI
/URI (https://c212.net/c/link/?t=0&l=en&o=3158192-1&h=212396788&u=https%3A%2F%2Fir.fusionpharma.com%2F2021-05-06-Fusion-Pharmaceuticals-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-Fusions-Targeted-Alpha-Therapy-TAT-in-Combination-with-Mercks-KEYTRUDA-R-pembrolizumab-in-Patients-With-Solid-Tumors-Expressing-IGF-1R&a=announced+that+it+has+entered+a+clinical+trial+collaboration+with+a+subsidiary+of+Merck)
>>
>>
endobj
10 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [282 395.250000 495.750000 403.500000 ]
/Border [0 0 0]
/A <<
/Type /Action
/S /URI
/URI (https://c212.net/c/link/?t=0&l=en&o=3158192-1&h=525714101&u=https%3A%2F%2Fir.fusionpharma.com%2F2021-04-10-Fusion-Pharmaceuticals-Announces-Preclinical-Combination-Data-Demonstrating-Enhanced-Efficacy-in-Multiple-Preclinical-Tumor-Models&a=preclinical+data+at+the+2021+AACR+Virtual+Annual+Meeting)
>>
>>
endobj
11 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [90.7500000 341.250000 522.750000 358.500000 ]
/Border [0 0 0]
/A <<
/Type /Action
/S /URI
/URI (https://c212.net/c/link/?t=0&l=en&o=3158192-1&h=1843814631&u=https%3A%2F%2Fir.fusionpharma.com%2F2021-04-01-Fusion-Pharmaceuticals-Announces-Closing-of-Acquisition-of-IPN-1087-a-Small-Molecule-Targeting-NTSR1-from-Ipsen&a=announced+the+closing+of+its+acquisition+of+Ipsen%27s+assets+and+intellectual+property+related+to+IPN-1087)
>>
>>
endobj
5 0 obj
<<
/Type /Page
/Parent 2 0 R
/Contents 12 0 R
/Resources 14 0 R
/Annots 15 0 R
/MediaBox [0 0 612 792]
>>
endobj
14 0 obj
<<
/ColorSpace <<
/PCSp 4 0 R
/CSp /DeviceRGB
/CSpg /DeviceGray
>>
/ExtGState <<
/GSa 3 0 R
>>
/Pattern <<
>>
/Font <<
/F6 6 0 R
/F7 7 0 R
>>
/XObject <<
>>
>>
endobj
15 0 obj
[ 8 0 R 9 0 R 10 0 R 11 0 R ]
endobj
12 0 obj
<<
/Length 13 0 R
/Filter /FlateDecode
>>
stream
x]K8v-JTUW"@bEГ`0=Hg-%>>d[=t%Q%y|sɱ̓?Veu}s?}?~Ǐ>ڿ|o!=ksןG~GǺ<]mxY2,ӏ8Gr,Ҵھ]~9oxMo>˘:_>
Ǐߊ)sO͔>{,MuoږbI惖Rm1v-F-:fie
ZsKqLp[ie{ˠ{sK~L&|Z:)ns4F-_B7l7
;oi&{P},VL74v3}*BΒمlloP`I27X4?AQm4M'Ob}̳~ퟒz<7@`ڬO3;3OG
X {l%1mϘaL=Ya/Lcnrw!Mgu,M;JXOKcLFY>1OѽkS|OZij